FILIP JANKU to Mitogen-Activated Protein Kinase 3
This is a "connection" page, showing publications FILIP JANKU has written about Mitogen-Activated Protein Kinase 3.
Connection Strength
0.184
-
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195.
Score: 0.147
-
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018 06; 81(6):1129-1141.
Score: 0.037